Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Eribulin in Previously Treated HER2-negative Metastatic Breast Cancer
KCT0003826Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, eribulin in breast cancer, sponsored by Ono Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
nivolumaberibulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003826.